Subcutaneous tetrodotoxin and inflammatory pain

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Peripheral tetrodotoxin (TTX) has been proposed for the treatment of several types of pain, and thus i.m. TTX is currently being evaluated in patients with severe cancer pain.1 In some animal studies, it appears that inflammatory pain may also be responsive to the antinociceptive effect of TTX, but the potency of the drug after systemic injection is not clear. Thus, the subcutaneous injection of TTX attenuated pain behaviour in the inflammatory phase of the rat formalin test,2 but one study reported lack of activity in the carrageenan model, where the drug only seemed effective when injected in the sciatic nerve.3